Dezima nabs $18.6M in venture cash; Aveo gets date on tivozanib review;

 @FierceBiotech: Ignyta, Lieden University team on rheumatoid arthritis biomarker research. Item | Release | Follow @FierceBiotech

@JohnCFierce: Sarepta spikes on disputed report of adverse events for rival GSK drug. Story | Follow @JohnCFierce

@RyanMFierce: Is Africa poised to play a bigger role in drug innovation? From Novartis: More | Follow @RyanMFierce

> Dutch biotech Dezima Pharma--which is working on developing new drugs in the field of dyslipidemia--raised a total of €14.2 million ($18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995) along with earlier-stage dyslipidemia assets. The A round was led by Forbion Capital Partners and BioGeneration Ventures, with participation from New Science Ventures. The company also gained a €4.4 million loan from an agency of the Dutch Ministry of Economic Affairs. Release

> Cambridge,MA-based Aveo ($AVEO) and its partner Astellas say they will have a May 2 FDA advisory committee review of its advanced renal cell carcinoma therapy tivozanib. Tivozanib has garnered mixed data in late-stage studies which will likely provide plenty of fodder for questions. Story

> Innovus Pharmaceuticals says it has signed a deal with Centric Research Institute for over $7.5 US million in upfront, milestones and sales royalty payments in order to acquire global ex- U.S. rights to the marketed skin cream, CIRCUMserum. Release

Pharma News

@FiercePharma: Trending: Top 10 Pharma Advertising Budgets - 2012. Special Report | Follow @FiercePharma

@EricPFierce: U.S. Supreme Court ruling against Amgen in class action investor case seen as hit to Pharma, other businesses. Story | Follow @EricPFierce

> Ex-Pfizer chief takes helm as Optimer puts out for-sale sign. Story

> Bayer bucks pharma trend with 'remarkable' growth in new drugs. Article

> Mylan eyes injectables domination with $1.6B Agila buy. News

Medical Device News

 @FierceMedDev: FDA: Spending cuts will delay product approvals. Item | Follow @FierceMedDev

 @MarkHFierce: Fierce 15 company CardioKinetix nailed down the second half of a $44M Series E. News | Follow @MarkHFierce

 @DamianFierce: Have a look at @FierceMedDev's top 10 moneymakers in medical devices. Special Report | Follow @DamianFierce

> Medtronic scores CE mark for novel TAVI valve. News

> Sorin commits $5M more to Israeli heart failure device startup, with option to buy. More

> Natus predicts 20% revenue soar in 2013. Article

Vaccines News

> FDA panel endorses quadrivalents, setting stage for new flu market. Article

> Is it too soon to quit on Nabi's nicotine vaccine? More

> Seasonal flu vaccine only 56% effective. Story

> GSK facing competition from Sanofi's 6-in-1 shot. Item

> After rejection, Dynavax to shoot for limited hep B vaccine approval. Report

Pharma Manufacturing News

> Ranbaxy problems overshadow manufacturing expansion. Article

> Qualicaps adds new technology as part of expansion. Item

> FDA warning to Abbey questions quality of API for sterile drugs. Story

> Hospira manufacturing problems arise at an inopportune time. More

And Finally… Alarmed by a spike in the number of antibiotic-resistant superbugs in the U.S., health officials have been issuing new warnings to hospitals and other likely breeding grounds for particularly dangerous variants. Story

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.